OCT 30, 2014 12:00 AM PDT

Cancer Study In Mice Brings Hope For Human Patients

A study conducted at the University of Chicago's Center for Personalized Therapeutics has shown remarkable results in eliminating human tumors that have been transplanted into mice. The new research, reported in the journal Science Translational Medicine, highlighted two drugs that were extremely effective and produced little or no side effects.

The drugs, OTS964 and its precursor OTS514, were given to mice that had been implanted with human cancer tumors. The drugs were given in two forms, intravenously and orally. Initially, the drugs showed toxicity to red and white blood cells, however once it was encased in liposomes, this toxicity was eliminated in the intravenous form and easily managed in the oral form.

The molecular target of this drug has been known for over a decade. TOPK (T-lymphocyte-activated killer cell-originated protein kinase) has always been associated with tumor growth. The protein is present in many kinds of human cancers, but the study looked at an especially aggressive lung tumor, LU-99. Researchers grew the tumors on the mice to 150 cubic millimeters and then injected the mice with OTS964, twice a week for three weeks. In five out of six of the mice, the tumors were completely eliminated. Even after the drug was stopped, the tumors continued to shrink.

The drug worked by preventing the tumor cells from dividing. TOPK is the agent that allows cancer cells to rapidly divide and spread disease. Without this protein, the cancer cells failed to divide and grow and essentially withered and died.

University of Chicago Professor of Medicine, Yusuke Nakamura, was excited by the results. "It is rare to see complete regression of tumors in a mouse model," he said. "Many drugs can repress the growth but it is uncommon to see them eradicated. This has rarely been reported."

Phase 1 clinical trials of the drug could begin as early as the fall of 2015
About the Author
  • I'm a writer living in the Boston area. My interests include cancer research, cardiology and neuroscience. I want to be part of using the Internet and social media to educate professionals and patients in a collaborative environment.
You May Also Like
MAY 30, 2018
Cell & Molecular Biology
MAY 30, 2018
Diagnosing Deadly Kidney Cancers Sooner
Researchers have found that deadly kidney cancers can be identified by assessing their evolutionary path, which is different for distinct types....
JUN 05, 2018
Cancer
JUN 05, 2018
Precision vs. Personalized Medicine Part II: Personalized Approach
So often the phrases "Precision Medicine" and "Personalized Medicine" are used interchangeably. Are they really synonyms? Part II looks at Personalized Medicine...
JUN 12, 2018
Cancer
JUN 12, 2018
CD44 Insights & Cancer Influence
CD44 is a known cell surface protein involved in numerous interactions; it is overexpressed in cancerous tissue and its isoforms are being investigated as targets for cancer immunotherapy...
JUL 18, 2018
Immunology
JUL 18, 2018
Immunotherapy Increases Survival of Melanoma Brain Metastases Patients
Use of Checkpoint Blockade Immunotherapy increases survival rates in Melanoma Brain Metastases patients, with a 4-year survival rate increase from 11.1% to 28.1%...
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 21, 2018
Cancer
AUG 21, 2018
'Zombie' gene returns to life and kills cancer in elephants
Researchers have discovered a gene that can protect elephants from cancer. An estimated 17 percent of humans worldwide die from cancer, but less than five ...
Loading Comments...